Analysis of Serum Antinuclear Antibody Expression Level and its Clinical Value in Patients with Cervical Cancer
Objective To investigate expression level of serum antinuclear antibody in patients with cervical cancer and its clinical value was discussed.Methods Cervical cancer patients and healthy women who underwent examina-tion in Xingyi People's Hospital from October 2022 to October 2023 were retrospectively selected as observation group and control group,with 46 cases in each group.The expression level of serum antinuclear antibody was detected in both groups,and the detection results of the two groups were compared.Results The total positive rate of observa-tion group was 54.35%(25/46),higher than 6.52%(3/46)of control group,the difference was statistically significant(χ2=24.848,P<0.05).The fluorescence pattern of antinuclear antibody(ANA)in observation group was predominantly nucleolar or speckled,and the occurrence rate were higher than those of control group,and the differences were statis-tically significant(both P<0.05).The proportion of patients with titer distribution of 1∶100 and 1∶320 in observation group were higher than those in control group,and the differences were statistically significant(both P<0.05).The positive rate of ANA in patients with stage Ⅲ to stage Ⅳ was higher than that in patients with stage Ⅰ to stage Ⅱ,and the difference was statistically significant(P<0.05).In the degree of differentiation,the ANA positive rate of low-differentiation patients was higher than that of medium-differentiation patients,and the difference was statistically sig-nificant(P<0.05).Conclusion The positive rate of ANA in patients with cervical cancer is higher,and the antibody ti-ter is higher than that in healthy people,and the positive rate of ANA may vary greatly depending on the differentia-tion degree and clinical stage,which should be paid attention to clinically.
NETL
NSTL
万方数据
